Health
ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses – Business Wire
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine
CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize the SARS-CoV-2 virus, including the E484K and N501Y mutations. The company presented the results in an oral presentation at the 28th Conference on Retroviruses and Opportunistic Infections (CROI) and published the positive findings of high binding affinity to the variants in preprint server, bioRxiv…
-
Noosa News18 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News17 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General21 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
General14 hours agoQantas ‘contacted by potential cybercriminal’ after attack on data of up to 6 million customers